Egypt Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report Download FREE Resources

Published: September 23, 2022 Report Code: GDHC0033CHR-ST

Select Item

Egypt Healthcare Market Report Overview

The Egyptian pharmaceutical market size is $3.0 billion in 2022 and will grow at a CAGR of more than 7% from 2022 to 2027. The following are some of the key highlights of the Egyptian pharmaceutical market:

  • Yemen, Saudi Arabia, Iraq, Sudan, and India are major export partners of pharmaceutical products.
  • Switzerland, the US, Germany, France, and China are major suppliers of medical equipment to Egypt.
  • Hospital supplies had the highest share in Egypt’s medical devices market, followed by cardiovascular devices, and orthopedic devices.
  • Generics was the largest segment in the Egyptian pharmaceutical market.

Egypt Pharmaceutical Market Overview, 2022-2027 ($ Billion)

Egypt Pharmaceutical Market Overview, 2022-2027 ($ Billion)

Buy The Full Report for More Insights on Egypt Pharmaceutical Market Forecast, Download a Free Report Sample

Pharmaceutical Market Size (2022) $3.0 Billion
Pharmaceutical CAGR (2022 – 2027) >7%
Pharmaceutical Market Segments Generic Drugs

Biologics

Biosimilars

Over the Counter (OTC) Medicines
Leading Companies (Pharmaceutical) Pfizer, Novartis, GlaxoSmithKline (GSK), Sanofi, and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO)
Medical Devices Market Size (2021) $4.0 Billion
Medical Devices CAGR (2022 – 2027) >3%
Medical Devices Market Segments Hospital Supplies

Cardiovascular Devices

Orthopedic Devices

General Surgery Devices

Wound Care Management
Leading Companies (Medical Devices) Abbott, Fresenius, Philips, Amplifon, and Amecath

Egypt Pharmaceutical Market

The Egyptian healthcare sector is going through a time of rapid change, which is opening huge prospects for investment. Egypt’s digital health business is seeing enormous development, proven progress, and important investments in terms of using artificial intelligence technology, mobile computing, and wearable devices to increase the efficiency and quality of cost-effective healthcare services, hence boosting healthcare standards and access in the country.​​ Furthermore, medical tourism in Egypt is gaining recognition owing to its favorable weather, proximity to Europe, low rates for both treatments and tourist facilities, a wide range of services at integrated medical institutions, and healthcare personnel with international education and training.​

The Egypt healthcare market research report gives an overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers. It profiles and provides a SWOT analysis of the major players in the pharmaceutical and medical device market. It also provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

Egypt Pharmaceutical Market Segments

The key segments of the Egyptian pharmaceutical market are generic drugs, biologics, biosimilars, and over-the-counter (OTC) medicines. Generics dominated the market owing to favorable pricing concessions by the government. ​

Egypt Medical Devices Market Analysis by Segments

Egypt Medical Devices Market Analysis by Segments

Buy The Full Report for More Insights on Egypt Pharmaceutical Market Segments, Download a Free Report Sample

Competitive Landscape

Some of the leading companies in the Egyptian pharmaceutical market are Pfizer, Novartis, GlaxoSmithKline (GSK), Sanofi, and Egyptian International Pharmaceuticals Industries Co SAE (EIPICO) among others. Pfizer led the Egyptian pharmaceutical market.

Egypt Pharmaceutical Market, by Leading Companies

Egypt Pharmaceutical Market, by Leading Companies

Buy The Full Report for More Insights on Companies in the Egypt Pharmaceutical Market, Download a Free Report Sample

Egypt Medical Devices Market Analysis

Egypt medical devices market value was $4.0 billion in 2021 and is expected to grow at a CAGR of more than 3% during 2022 – 2027. The Egyptian medical devices market is the second largest in the MENA region. The production of medical devices in Egypt is very low, and most medical devices are supplied by imports. The El Gomhoureya is a government-owned company in Egypt that imports and distributes medical devices to the public healthcare sector. The technical equipment includes radiography and ultrasound apparatus, vital statistic monitors, dialysis machines, and laboratory microscopes.

Egypt Medical Devices Market Overview, 2022-2027 ($ Billion)

Egypt Medical Devices Market Overview, 2022-2027 ($ Billion)

Buy The Full Report for More Insights on Egypt Medical Devices Market, Download a Free Report Sample

Egypt Medical Devices Market Segments

The Egyptian medical devices market segments are hospital supplies, cardiovascular devices, orthopedic devices, general surgery devices, and wound care management among others. Hospital supplies was followed by cardiovascular devices and orthopedic devices.

Egypt Medical Devices Market Analysis by Segments

Egypt Medical Devices Market Analysis by Segments

Buy The Full Report for More Insights on Segments in the Egypt Medical Devices Market, Download a Free Report Sample

Competitive Landscape

Some of the leading companies in the Egyptian medical devices market are Abbott, Fresenius, Philips, Amplifon, and Amecath among others. Abbott led the Egyptian medical devices market.

Egypt Medical Devices Market, by Leading Players

Egypt Medical Devices Market, by Leading Players

Buy The Full Report for More Insights on Companies in the Egypt Medical Devices Market, Download a Free Report Sample

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Egyptian healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the Egypt healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts about the Egypt Healthcare Market

2.3 Key Highlights: Healthcare Startups in Egypt

2.4 Key Events: Egypt Healthcare Industry, 2016–22

2.5 Key Events: Egypt Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2020–22

2.7 Key Events: Top Completed Deals by Value, 2020-22

2.8 Country Profile, Egypt, 2022

3. Overview of the Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Egypt

3.5 Pharmaceutical Market – Market Segments

3.6 Major Therapeutic Areas, Egypt

3.7 COVID-19 Epidemiology, Egypt

3.8 COVID-19 Impact and Developments, Egypt

3.9 COVID-19 Impact and Developments in the Healthcare Market, Egypt

3.10 COVID-19 Clinical Trials Landscape, Egypt

3.11 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Egypt, 2020–22

6.2 Deal Analysis: Medical Device Market, Egypt, 2020–22

7. HealthTech Landscape

7.1 HealthTech Landscape, Egypt

7.2 HealthTech Deals Landscape, Egypt

7.3 Key HealthTech Deals, Egypt

7.4 Adoption of Technology in Healthcare, Egypt

7.5 Digital Statistics, Egypt

7.6 Digital Healthcare Regulations, Egypt

7.7 HealthTech Landscape: Benefits and Risks, Egypt

8. Market Access

8.1 Overview of Healthcare System, Egypt

8.2 Reimbursement Process, Egypt

8.3 Overview of Public and Private Insurance Providers, Egypt

8.4 Healthcare Spending and Health Price Trends, Egypt

8.5 Pricing Policies, Egypt

8.6 Market Access: Key Events Timeline, Egypt, 2010–21

8.7 Regulatory Landscape, Egypt

8.7.1 Overview of Regulatory Agencies, Egypt

8.7.2 Marketing Authorization for Pharmaceutical Products, Egypt

8.7.3 Marketing Authorization for Medical Devices, Egypt

8.7.4 Intellectual Property Rights, Patent, Egypt

8.7.5 Intellectual Property Rights, Trademark, Egypt

8.7.6 Clinical Trial Regulation Process, Egypt

8.7.7 Pharmaceutical Clinical Trials Landscape, Egypt

8.7.8 Medical Device Clinical Trials Landscape, Egypt

8.7.9 Pharmaceutical Product Export Regulations, Egypt

8.7.10 Pharmaceutical Product Import Regulations, Egypt

8.7.11 Pharmaceutical Advertising Regulations, Egypt

8.7.12 Labeling and Packaging Regulations, Egypt

9. Country Healthcare Landscape

9.1 Egypt Healthcare Policy Highlights

9.2 Healthcare Facilities, Egypt

9.3 Life Expectancy and Immunization Rate, Egypt

9.4 Environmental Health, Egypt

9.5 Healthcare Personnel, Egypt

9.6 Disease Burden, Egypt

9.7 Healthcare Expenditure, Egypt

10 Trade Associations, Egypt

11 Trade Fairs, Egypt

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Pharmaceutical price mark-ups, Egypt, 2018

Table 2: Major therapeutic areas by costs of treatment, Egypt, 2020

Table 3: COVID-19 indicators (number), Egypt and Global, 2022

Table 4: Top COVID-19 markets by product categories (number of available marketed products), Egypt, 2020–22

Table 5: Available COVID-19 vaccines, Egypt, 2022

Table 6: Medical devices market, major segments ($M), Egypt, 2021

Table 7: Classification of medical devices, Egypt, 2022

Table 8: Patent fees, Egypt, 2022

Table 9: Trade fairs, Egypt, 2022

Figures

Figure 1: Pharmaceutical market, revenue (EGPB and $B), Egypt, 2014–21

Figure 2: Medical devices market, revenue ($B), Egypt, 2016–22

Figure 3: Healthcare startups in Egypt, 2022

Figure 4: Country profile, Egypt, 2022

Figure 5: Pharmaceutical market, revenue (EGPB and $B), Egypt, 2014–21

Figure 6: Pharmaceutical market, revenue forecast (EGPB and $B), Egypt, 2022–27

Figure 7: Pharmaceutical exports ($M), Egypt, 2014–21

Figure 8: Top export partners, Egypt, 2021

Figure 9: Pharmaceutical imports ($B), Egypt, 2014–21

Figure 10: Top import partners, Egypt, 2021

Figure 11: Pharmaceutical supply channels, Egypt, 2022

Figure 12: Top medical tourism clinics and hospitals, Egypt, 2022

Figure 13: Common treatments offered to medical tourists, Egypt, 2022

Figure 14: OTC medicines market, revenue ($M), Egypt, 2016–21

Figure 15: OTC market by sub-categories of drugs, revenue ($M), Egypt, 2021

Figure 16: Major therapeutic areas by costs of treatment, Egypt, 2020

Figure 17: COVID-19 (number of cases), Egypt, 2020–22

Figure 18: COVID-19 (number of deaths), Egypt, 2020–22

Figure 19: Stringency index, COVID-19, Egypt, 2020–22

Figure 20: Containment and health index, COVID-19, Egypt, 2020–22

Figure 21: Top COVID-19 markets by product categories (number of available marketed products), Egypt, 2020–22

Figure 22: COVID-19 vaccine doses administration, number of vaccine doses administered, Egypt, 2021-22

Figure 23: COVID-19 vaccine booster doses administration, number of booster doses administered per 100 population, Egypt, 2022

Figure 24: COVID-19 clinical trial sponsors by trial count, Egypt, 2020–22

Figure 25: COVID-19 clinical trials count by phase, Egypt, 2020–22

Figure 26: COVID-19 clinical trials count by trial status, Egypt, 2020–22

Figure 27: Medical devices market, revenue ($B), Egypt 2016–21

Figure 28: Medical devices market, revenue forecast ($B), Egypt 2022–27

Figure 29: Medical devices market, major segments (%), Egypt, 2021

Figure 30: Hospital supplies market, revenue ($M), Egypt, 2017–27

Figure 31: Cardiovascular devices market, revenue ($M), Egypt, 2017–27

Figure 32: Orthopedic devices market, revenue ($M), Egypt, 2017–27

Figure 33: General surgery devices market, revenue ($M), Egypt, 2017–27

Figure 34: Wound care management devices market, revenue ($M), Egypt, 2017–27

Figure 35: Diagnostics market, revenue ($M), Egypt, 2016–21

Figure 36: Diagnostics market, revenue forecast ($M), Egypt, 2022–27

Figure 37: Medical devices market, revenue ($B) of major companies, Egypt, 2021

Figure 38: Deal value and deal count, pharmaceutical market, Egypt, 2020–22

Figure 39: Deal value and deal count, quarterly, pharmaceutical market, Egypt, 2020–22

Figure 40: Deal value and deal count subtypes, pharmaceutical market, Egypt, 2020–22

Figure 41: Deal value and deal count, medical devices market, Egypt, 2020–22

Figure 42: Deal value and deal count, quarterly, medical devices market, Egypt, 2020–22

Figure 43: Deal value and deal count subtypes, medical devices market, Egypt, 2020–22

Figure 44: Top equipment sectors by deal value ($M), medical devices market, Egypt, 2020–22

Figure 45: Top equipment sectors by deal count, medical devices market, Egypt, 2020–22

Figure 46: M&A deals, quarterly (by value and by number), medical devices market, Egypt, 2020–22

Figure 47: VC deals quarterly, (by value and by number), medical devices market, Egypt, 2020–22

Figure 48: Deal value ($M) and deal count (number of deals), HealthTech, Egypt, 2020–22

Figure 49: Deal value ($M) and deal count (number of deals) by deal sub-category, HealthTech, Egypt, 2020–22

Figure 50: Overview of healthcare system, Egypt, 2022

Figure 51: Medicine reimbursement process, Egypt, 2022

Figure 52: New governance structure of the UHI System as per the UHI Law, Egypt, 2019

Figure 53: OOP expenditure (% of total expenditure on health), Egypt, 2012–21

Figure 54: Annual rate of change in healthcare Consumer Price Index (CPI) (base year= 2019), Egypt, 2013–20

Figure 55: Egyptian Drug Authority, organization chart, Egypt, 2022

Figure 56: EDA drug approval process part 1, Egypt, 2022

Figure 57: EDA drug approval process part 2, Egypt, 2022

Figure 58: Organization structure for clinical trial regulation, Egypt, 2022

Figure 59: Pharmaceutical clinical trials count by trial status, Egypt, 2021–22

Figure 60: Pharmaceutical clinical trials count by phase, Egypt, 2021–22

Figure 61: Top five pharmaceutical clinical trials sponsors by count, Egypt, 2021–22

Figure 62: Pharmaceutical clinical trials count by therapy area, Egypt, 2021–22

Figure 63: Medical device clinical trials count by trial status, Egypt, 2021–22

Figure 64: Medical device clinical trials count by market categories, Egypt, 2021–22

Figure 65: Top five medical device clinical trials sponsors by count, Egypt, 2021–22

Figure 66: Medical device clinical trials count by therapy area, Egypt, 2021–22

Figure 67: Labeling on pharmaceutical products, Egypt, 2022

Figure 68: Labeling elements of medical devices, Egypt, 2022

Figure 69: Number of hospital beds (per 1,000 population), Egypt, 2015–22

Figure 70: Number of hospitals, Egypt, 2015–22

Figure 71: Number of beds by type in authorities supervised by the Ministry of Health and Population, Egypt, 2019

Figure 72: Number of CT scanners (absolute units), Egypt, 2015–22

Figure 73: Number of MRI units (absolute units), Egypt, 2015–22

Figure 74: Immunization rate (%), Egypt, 2015–22

Figure 75: Life expectancy of males and females at birth (years), Egypt, 2015–22

Figure 76: CO2 emissions (million tons), Egypt, 2015–22

Figure 77: PM2.5 (µg per m3), Egypt, 2015–22

Figure 78: Doctors (per 1,000 population), Egypt, 2015–22

Figure 79: Dentists (per 1,000 population), Egypt, 2015–22

Figure 80: Pharmacists (per 1,000 population), Egypt, 2015–22

Figure 81: Nurses (per 1,000 population), Egypt, 2015–22

Figure 82: Major causes of mortality (per 100,000 population), Egypt, 2019

Figure 83: Major causes of male mortality (per 100,000 population), Egypt, 2019

Figure 84: Major causes of female mortality (per 100,000 population), Egypt, 2019

Figure 85: DALYs by major disease (per 100,000 population), Egypt, 2019

Figure 86: Healthcare expenditure as a percentage of GDP (%), Egypt, 2015–22

Figure 87: Health expenditure share (% of total health spending), Egypt, 2015–22

Frequently asked questions

Egypt Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,992

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Egypt Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Pharmaceuticals
New
Pharmaceutical Drug Development Annual Review 2025
$1,200 | August 2026
Pharmaceuticals
New
Q2 2026 CRO Activity and Intel Report
$1,870 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Egypt Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Egypt Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more